The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on da...

Full description

Saved in:
Bibliographic Details
Published inBlood cancer journal (New York) Vol. 11; no. 8; p. 138
Main Authors Terpos, Evangelos, Gavriatopoulou, Maria, Ntanasis-Stathopoulos, Ioannis, Briasoulis, Alexandros, Gumeni, Sentiljana, Malandrakis, Panagiotis, Fotiou, Despina, Papanagnou, Eleni-Dimitra, Migkou, Magdalini, Theodorakakou, Foteini, Roussou, Maria, Eleutherakis-Papaiakovou, Evangelos, Kanellias, Nikolaos, Trougakos, Ioannis P., Kastritis, Efstathios, Dimopoulos, Meletios A.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 02.08.2021
Springer Nature B.V
Nature Publishing Group
Subjects
13/1
14/1
631/250/2152/2153/1291
692/699/1541/1990/804
82/1
96/1
Antibodies
Biomedical and Life Sciences
Biomedicine
Cancer Research
Coronaviruses
COVID-19 vaccines
Hematology
Immunization
Multiple myeloma
Oncology
Severe acute respiratory syndrome coronavirus 2
Online AccessGet full text

Cover

Abstract Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on days 1 (before the first vaccine shot), 22, and 50. Patients with MM ( n  = 213), SMM ( n  = 38), and MGUS ( n  = 25) and 226 healthy controls were enrolled in the study (NCT04743388). Vaccination with either two doses of the BNT162b2 or one dose of the AZD1222 vaccine leads to lower production of NAbs in patients with MM compared with controls both on day 22 and on day 50 ( p  < 0.001 for all comparisons). Furthermore, MM patients showed an inferior NAb response compared with MGUS on day 22 ( p  = 0.009) and on day 50 ( p  = 0.003). Importantly, active treatment with either anti-CD38 monoclonal antibodies (Mabs) or belantamab mafodotin and lymphopenia at the time of vaccination were independent prognostic factors for suboptimal antibody response following vaccination. In conclusion, MM patients have low humoral response following SARS-CoV-2 vaccination, especially under treatment with anti-CD38 or belamaf. This underlines the need for timely vaccination, possibly during a treatment-free period, and for continuous vigilance on infection control measures in non-responders.
AbstractList Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on days 1 (before the first vaccine shot), 22, and 50. Patients with MM ( n  = 213), SMM ( n  = 38), and MGUS ( n  = 25) and 226 healthy controls were enrolled in the study (NCT04743388). Vaccination with either two doses of the BNT162b2 or one dose of the AZD1222 vaccine leads to lower production of NAbs in patients with MM compared with controls both on day 22 and on day 50 ( p  < 0.001 for all comparisons). Furthermore, MM patients showed an inferior NAb response compared with MGUS on day 22 ( p  = 0.009) and on day 50 ( p  = 0.003). Importantly, active treatment with either anti-CD38 monoclonal antibodies (Mabs) or belantamab mafodotin and lymphopenia at the time of vaccination were independent prognostic factors for suboptimal antibody response following vaccination. In conclusion, MM patients have low humoral response following SARS-CoV-2 vaccination, especially under treatment with anti-CD38 or belamaf. This underlines the need for timely vaccination, possibly during a treatment-free period, and for continuous vigilance on infection control measures in non-responders.
Abstract Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on days 1 (before the first vaccine shot), 22, and 50. Patients with MM (n = 213), SMM (n = 38), and MGUS (n = 25) and 226 healthy controls were enrolled in the study (NCT04743388). Vaccination with either two doses of the BNT162b2 or one dose of the AZD1222 vaccine leads to lower production of NAbs in patients with MM compared with controls both on day 22 and on day 50 (p < 0.001 for all comparisons). Furthermore, MM patients showed an inferior NAb response compared with MGUS on day 22 (p = 0.009) and on day 50 (p = 0.003). Importantly, active treatment with either anti-CD38 monoclonal antibodies (Mabs) or belantamab mafodotin and lymphopenia at the time of vaccination were independent prognostic factors for suboptimal antibody response following vaccination. In conclusion, MM patients have low humoral response following SARS-CoV-2 vaccination, especially under treatment with anti-CD38 or belamaf. This underlines the need for timely vaccination, possibly during a treatment-free period, and for continuous vigilance on infection control measures in non-responders.
Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated in 276 patients with plasma cell neoplasms after vaccination with either the BNT162b2 or the AZD1222 vaccine, on days 1 (before the first vaccine shot), 22, and 50. Patients with MM (n = 213), SMM (n = 38), and MGUS (n = 25) and 226 healthy controls were enrolled in the study (NCT04743388). Vaccination with either two doses of the BNT162b2 or one dose of the AZD1222 vaccine leads to lower production of NAbs in patients with MM compared with controls both on day 22 and on day 50 (p < 0.001 for all comparisons). Furthermore, MM patients showed an inferior NAb response compared with MGUS on day 22 (p = 0.009) and on day 50 (p = 0.003). Importantly, active treatment with either anti-CD38 monoclonal antibodies (Mabs) or belantamab mafodotin and lymphopenia at the time of vaccination were independent prognostic factors for suboptimal antibody response following vaccination. In conclusion, MM patients have low humoral response following SARS-CoV-2 vaccination, especially under treatment with anti-CD38 or belamaf. This underlines the need for timely vaccination, possibly during a treatment-free period, and for continuous vigilance on infection control measures in non-responders.
ArticleNumber 138
Author Malandrakis, Panagiotis
Terpos, Evangelos
Eleutherakis-Papaiakovou, Evangelos
Trougakos, Ioannis P.
Ntanasis-Stathopoulos, Ioannis
Gavriatopoulou, Maria
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Roussou, Maria
Papanagnou, Eleni-Dimitra
Briasoulis, Alexandros
Kanellias, Nikolaos
Gumeni, Sentiljana
Dimopoulos, Meletios A.
Kastritis, Efstathios
Author_xml – sequence: 1
  givenname: Evangelos
  orcidid: 0000-0001-5133-1422
  surname: Terpos
  fullname: Terpos, Evangelos
  email: eterpos@med.uoa.gr
  organization: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens
– sequence: 2
  givenname: Maria
  orcidid: 0000-0002-6244-1229
  surname: Gavriatopoulou
  fullname: Gavriatopoulou, Maria
  organization: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens
– sequence: 3
  givenname: Ioannis
  orcidid: 0000-0002-6328-9783
  surname: Ntanasis-Stathopoulos
  fullname: Ntanasis-Stathopoulos, Ioannis
  organization: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens
– sequence: 4
  givenname: Alexandros
  surname: Briasoulis
  fullname: Briasoulis, Alexandros
  organization: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens
– sequence: 5
  givenname: Sentiljana
  orcidid: 0000-0003-0033-2008
  surname: Gumeni
  fullname: Gumeni, Sentiljana
  organization: Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens
– sequence: 6
  givenname: Panagiotis
  surname: Malandrakis
  fullname: Malandrakis, Panagiotis
  organization: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens
– sequence: 7
  givenname: Despina
  surname: Fotiou
  fullname: Fotiou, Despina
  organization: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens
– sequence: 8
  givenname: Eleni-Dimitra
  surname: Papanagnou
  fullname: Papanagnou, Eleni-Dimitra
  organization: Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens
– sequence: 9
  givenname: Magdalini
  surname: Migkou
  fullname: Migkou, Magdalini
  organization: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens
– sequence: 10
  givenname: Foteini
  surname: Theodorakakou
  fullname: Theodorakakou, Foteini
  organization: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens
– sequence: 11
  givenname: Maria
  surname: Roussou
  fullname: Roussou, Maria
  organization: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens
– sequence: 12
  givenname: Evangelos
  surname: Eleutherakis-Papaiakovou
  fullname: Eleutherakis-Papaiakovou, Evangelos
  organization: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens
– sequence: 13
  givenname: Nikolaos
  surname: Kanellias
  fullname: Kanellias, Nikolaos
  organization: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens
– sequence: 14
  givenname: Ioannis P.
  surname: Trougakos
  fullname: Trougakos, Ioannis P.
  organization: Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens
– sequence: 15
  givenname: Efstathios
  orcidid: 0000-0001-8191-5832
  surname: Kastritis
  fullname: Kastritis, Efstathios
  organization: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens
– sequence: 16
  givenname: Meletios A.
  orcidid: 0000-0001-8990-3254
  surname: Dimopoulos
  fullname: Dimopoulos, Meletios A.
  organization: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens
BookMark eNp9kstu3SAQhq0qVZOmeYGukLrpxi0Y8GVTqTq9HSlSNmm3CMPY5sgGF3Aq9yX6yuUcp5d0UTaM4Jt_mJ95mp1ZZyHLnhP8imBavw6MMFznuCA5xpzinD7KLgrMWM5pzc_-is-zqxAOOC1ekoY0T7JzyigjlPKL7MftAMjCEr0czXdjeyRtNK3TK_IQZmcDoNmFiHY3X_bvctKgO6mUsTIaZ5GxaE4R2BjQNxMHNK0wukkiE9Bg-mFckYYZrE4ESnxMxeI6A3LdqU7-i48eZJwS9Sx73MkxwNX9fpl9_vD-dvcpv775uN-9vc4VJ1XMFatVaq3TulKcQ9eRmjeSEZ38qCsCTUNLojotSVMQxmnXcGg6VfG21oArSi-z_aarnTyI2ZtJ-lU4acTpwPleSB-NGkEwWXeYtaWmGFhZ8ratoJClTtXLplQ4ab3ZtOalnUCr1EZy84HowxtrBtG7O1HTokqfkgRe3gt493WBEMVkgoJxlBbcEkTBecVZyYsioS_-QQ9u8TZZdaJoGo3qSBUbpbwLwUP3-zEEi-P4iG18RLJLnMZHHC2hW1JIsO3B_5H-T9ZPBxHKJw
CitedBy_id crossref_primary_10_1016_j_critrevonc_2022_103623
crossref_primary_10_1080_10428194_2022_2074989
crossref_primary_10_3389_fonc_2023_1208741
crossref_primary_10_1002_ajh_26406
crossref_primary_10_1002_ajh_26766
crossref_primary_10_1016_j_htct_2023_08_002
crossref_primary_10_1111_bjh_18212
crossref_primary_10_1182_bloodadvances_2023011658
crossref_primary_10_1136_jitc_2022_004766
crossref_primary_10_1038_s41408_022_00608_6
crossref_primary_10_1177_25151355231190497
crossref_primary_10_1002_ajh_26762
crossref_primary_10_1016_j_ekir_2022_05_031
crossref_primary_10_1080_14760584_2022_2008245
crossref_primary_10_1097_HS9_0000000000000800
crossref_primary_10_1007_s00277_022_04799_7
crossref_primary_10_1038_s41408_022_00684_8
crossref_primary_10_1016_j_eclinm_2023_102040
crossref_primary_10_3389_fimmu_2022_899972
crossref_primary_10_1007_s12185_022_03300_4
crossref_primary_10_1097_HS9_0000000000000764
crossref_primary_10_1182_blood_2022016317
crossref_primary_10_31857_S0042132423030055
crossref_primary_10_1097_HS9_0000000000000688
crossref_primary_10_1038_s41408_022_00752_z
crossref_primary_10_1038_s41409_022_01675_w
crossref_primary_10_3390_cancers15082266
crossref_primary_10_5937_smclk3_35474
crossref_primary_10_1182_bloodadvances_2023011063
crossref_primary_10_1007_s00277_022_04906_8
crossref_primary_10_1016_j_trim_2022_101713
crossref_primary_10_1186_s12985_022_01858_3
crossref_primary_10_1016_j_esmoop_2022_100403
crossref_primary_10_1093_oncolo_oyac032
crossref_primary_10_1111_bjh_17877
crossref_primary_10_1038_s41375_023_01920_1
crossref_primary_10_1016_j_ccell_2022_03_013
crossref_primary_10_1158_2643_3230_BCD_22_0173
crossref_primary_10_1002_ajh_26753
crossref_primary_10_1182_blood_2021014989
crossref_primary_10_26508_lsa_202201479
crossref_primary_10_3389_fonc_2023_1078725
crossref_primary_10_3390_vaccines10030374
crossref_primary_10_1038_s41571_022_00610_8
crossref_primary_10_1016_S2352_3026_21_00278_7
crossref_primary_10_2139_ssrn_3929967
crossref_primary_10_3390_vaccines10020182
crossref_primary_10_3390_cancers15143598
crossref_primary_10_1186_s13690_022_00935_x
crossref_primary_10_3389_fonc_2021_759108
crossref_primary_10_3324_haematol_2021_279895
crossref_primary_10_2490_prm_20230007
crossref_primary_10_1111_bjh_18714
crossref_primary_10_1158_2159_8290_CD_21_1368
crossref_primary_10_1093_bmb_ldac025
crossref_primary_10_1001_jamaoncol_2021_5942
crossref_primary_10_3390_biomedicines10020204
crossref_primary_10_1111_bjh_18434
crossref_primary_10_1111_bjh_18079
crossref_primary_10_1182_bloodadvances_2022008530
crossref_primary_10_3390_vaccines11020486
crossref_primary_10_1111_imj_16303
crossref_primary_10_2298_MPNS22S1115B
crossref_primary_10_3390_cancers13174480
crossref_primary_10_1016_j_clml_2022_03_012
crossref_primary_10_1016_j_ijid_2024_107108
crossref_primary_10_1007_s00277_023_05572_0
crossref_primary_10_3390_cancers14235816
crossref_primary_10_1134_S2079086423040035
crossref_primary_10_1038_s41408_021_00597_y
crossref_primary_10_1016_j_blre_2023_101077
crossref_primary_10_1177_03000605221086155
crossref_primary_10_1186_s13027_022_00454_y
crossref_primary_10_1038_s41408_021_00594_1
crossref_primary_10_1182_blood_2021014124
crossref_primary_10_3390_vaccines12050518
crossref_primary_10_3389_fonc_2023_1117815
crossref_primary_10_3390_jcm10235499
crossref_primary_10_1080_13696998_2021_2002063
crossref_primary_10_1080_10428194_2022_2131414
crossref_primary_10_1080_2162402X_2022_2120275
crossref_primary_10_1182_bloodadvances_2021006333
crossref_primary_10_1097_HS9_0000000000000677
crossref_primary_10_1158_2643_3230_BCD_21_0139
crossref_primary_10_1200_JCO_21_02257
crossref_primary_10_1200_EDBK_359656
crossref_primary_10_1007_s00277_023_05350_y
crossref_primary_10_1007_s12288_022_01528_y
crossref_primary_10_1016_j_cmi_2021_09_036
crossref_primary_10_3324_haematol_2021_280163
crossref_primary_10_1016_j_jinf_2022_11_013
crossref_primary_10_3390_vaccines10020164
crossref_primary_10_1016_j_ejim_2022_11_009
crossref_primary_10_1016_j_intimp_2022_109046
Cites_doi 10.1016/j.annonc.2020.04.475
10.1056/NEJMoa2027906
10.1016/S1470-2045(14)70442-5
10.1182/blood-2015-12-687749
10.3324/haematol.2019.231860
10.1016/S1473-3099(18)30601-7
10.1182/blood.2020008824
10.1007/s10238-020-00671-y
10.1016/j.annonc.2020.10.473
10.1038/s41375-020-0855-4
10.1016/j.cell.2020.02.058
10.1016/j.clml.2017.02.025
10.1038/s41408-020-00372-5
10.1016/S0140-6736(21)00432-3
10.1182/blood.2020008150
10.3389/fonc.2020.599098
10.1007/s10238-020-00648-x
10.18632/oncotarget.18085
10.1016/j.blre.2019.01.001
10.1056/NEJMoa2034577
10.3324/haematol.2014.116772
10.1038/s41375-020-0876-z
10.1186/s13045-021-01090-6
10.1038/s41586-020-2550-z
10.1158/1078-0432.CCR-20-1781
10.1016/S1470-2045(20)30310-7
10.1038/s41587-020-0631-z
10.1182/blood.2020006540
10.1097/HS9.0000000000000547
10.1001/jama.2021.2352
10.1002/ijc.33148
10.1016/j.cell.2020.02.052
10.1038/s41375-018-0133-x
10.1038/s41375-020-01016-0
10.1001/jama.2021.3341
10.1093/cid/ciaa1079
10.1038/s41375-020-01030-2
10.1158/1078-0432.CCR-18-1597
10.1007/s00262-008-0620-4
10.3324/haematol.2020.262758
10.1002/ajh.26185
10.1001/jamaoncol.2021.1218
10.1002/ajh.26248
10.1016/j.jinf.2021.05.004
10.1038/s41591-021-01377-8
10.3390/microorganisms9030546
10.1182/blood.2021011904
10.1002/ajh.26263
10.1111/bjh.17256
ContentType Journal Article
Copyright The Author(s) 2021
The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2021
– notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1038/s41408-021-00530-3
DatabaseName SpringerOpen
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection (Proquest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
Coronavirus Research Database
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef



Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: SpringerOpen
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ, Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2044-5385
EndPage 138
ExternalDocumentID oai_doaj_org_article_4a8f04b6d30e4665bb7e2a6d5fd696c0
10_1038_s41408_021_00530_3
GrantInformation_xml – fundername: We thank SYN-ENOSIS (Greece), IEMBITHEK (Greece), Genesis (Greece) and Nikolao and Theano Vafeia for partially funding this study.
– fundername: ;
GroupedDBID 0R~
3V.
53G
5VS
7X7
88E
8FI
8FJ
AAJSJ
ABUWG
ACGFS
ACSMW
ADBBV
AENEX
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBLON
EBS
EJD
EMOBN
FRP
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
KQ8
M1P
M48
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
W2D
AAYXX
CITATION
7XB
8FK
AZQEC
COVID
DWQXO
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c517t-c48c385fdd7c55eff1859a41d021871e99361cfda1921453f95e9fc75b8de0733
IEDL.DBID RPM
ISSN 2044-5385
IngestDate Tue Oct 22 15:13:49 EDT 2024
Tue Sep 17 21:25:13 EDT 2024
Fri Oct 25 02:17:07 EDT 2024
Thu Oct 10 18:16:22 EDT 2024
Fri Nov 22 00:25:04 EST 2024
Fri Oct 11 20:44:47 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c517t-c48c385fdd7c55eff1859a41d021871e99361cfda1921453f95e9fc75b8de0733
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-6328-9783
0000-0001-8990-3254
0000-0002-6244-1229
0000-0001-8191-5832
0000-0001-5133-1422
0000-0003-0033-2008
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327056/
PMID 34341335
PQID 2557303872
PQPubID 2041967
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_4a8f04b6d30e4665bb7e2a6d5fd696c0
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8327056
proquest_miscellaneous_2557546522
proquest_journals_2557303872
crossref_primary_10_1038_s41408_021_00530_3
springer_journals_10_1038_s41408_021_00530_3
PublicationCentury 2000
PublicationDate 2021-08-02
PublicationDateYYYYMMDD 2021-08-02
PublicationDate_xml – month: 08
  year: 2021
  text: 2021-08-02
  day: 02
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Blood cancer journal (New York)
PublicationTitleAbbrev Blood Cancer J
PublicationYear 2021
Publisher Nature Publishing Group UK
Springer Nature B.V
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Springer Nature B.V
– name: Nature Publishing Group
References Casneuf, Adams, van de Donk, Abraham, Bald, Vanhoof (CR41) 2021; 35
Dumontet, Hulin, Dimopoulos, Belch, Dispenzieri, Ludwig (CR15) 2018; 32
Voysey, Costa Clemens, Madhi, Weckx, Folegatti, Aley (CR26) 2021; 397
Galustian, Meyer, Labarthe, Dredge, Klaschka, Henry (CR47) 2009; 58
Gavriatopoulou, Ntanasis-Stathopoulos, Korompoki, Fotiou, Migkou, Tzanninis (CR5) 2020; 21
Gavriatopoulou, Korompoki, Fotiou, Ntanasis-Stathopoulos, Psaltopoulou, Kastritis (CR3) 2020; 20
CR33
CR30
Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler, Erichsen (CR1) 2020; 181
Martínez-López, Mateos, Encinas, Sureda, Hernández-Rivas, Lopez de la Guía (CR16) 2020; 10
Gharpure, Patel, Link-Gelles (CR27) 2021; 325
Leone, Solimando, Malerba, Fasano, Buonavoglia, Pappagallo (CR36) 2020; 10
Saadat, Rikhtegaran Tehrani, Logue, Newman, Frieman, Harris (CR28) 2021; 325
Solodky, Galvez, Russias, Detourbet, N'Guyen-Bonin, Herr (CR13) 2020; 31
Chamilos, Lionakis, Kontoyiannis (CR9) 2021; 72
CR4
Girmenia, Cavo, Offidani, Scaglione, Corso, Di Raimondo (CR24) 2019; 34
Yang, Sheng, Huang, Jin, Xiong, Jiang (CR7) 2020; 21
Liu, Zeng, Tao, Shi, COVID- in Cancer Patients Research, Wang (CR12) 2020; 147
CR49
CR48
Rajkumar, Dimopoulos, Palumbo, Blade, Merlini, Mateos (CR32) 2014; 15
Terpos, Engelhardt, Cook, Gay, Mateos, Ntanasis-Stathopoulos (CR18) 2020; 34
Nakamura, Smyth, Martinet (CR37) 2020; 136
Gavriatopoulou, Ntanasis-Stathopoulos, Korompoki, Terpos, Dimopoulos (CR20) 2021; 5
Walls, Park, Tortorici, Wall, McGuire, Veesler (CR2) 2020; 181
Costa, Vescovini, Bolzoni, Marchica, Storti, Toscani (CR46) 2017; 8
Cucinotta, Vanelli (CR6) 2020; 91
Mikulska, Cesaro, de Lavallade, Di Blasi, Einarsdottir, Gallo (CR38) 2019; 19
Le Bert, Tan, Kunasegaran, Tham, Hafezi, Chia (CR51) 2020; 584
CR19
Pimpinelli, Marchesi, Piaggio, Giannarelli, Papa, Falcucci (CR31) 2021; 14
Branagan, Duffy, Albrecht, Cooper, Seropian, Parker (CR40) 2017; 17
Pierceall, Amatangelo, Bahlis, Siegel, Rahman, Van Oekelen (CR43) 2020; 26
CR52
CR50
Chari, Samur, Martinez-Lopez, Cook, Biran, Yong (CR8) 2020; 136
Vijenthira, Gong, Fox, Booth, Cook, Fattizzo (CR10) 2020; 136
Ludwig, Boccadoro, Moreau, San-Miguel, Cavo, Pawlyn (CR23) 2021; 35
Krejcik, Casneuf, Nijhof, Verbist, Bald, Plesner (CR42) 2016; 128
Hahn, Schnitzler, Schweiger, Kunz, Ho, Goldschmidt (CR39) 2015; 100
Walsh, Frenck, Falsey, Kitchin, Absalon, Gurtman (CR35) 2020; 383
CR29
Polack, Thomas, Kitchin, Absalon, Gurtman, Lockhart (CR25) 2020; 383
Frerichs, Bosman, van Velzen, Fraaij, Koopmans, Rimmelzwaan (CR45) 2020; 105
CR22
CR21
Tan, Chia, Qin, Liu, Chen, Tiu (CR34) 2020; 38
Marra, Generali, Zagami, Cervoni, Gandini, Venturini (CR11) 2021; 32
Roeker, Knorr, Pessin, Ramanathan, Thompson, Leslie (CR14) 2020; 34
Moreno, Perez, Zabaleta, Manrique, Alignani, Ajona (CR44) 2019; 25
Engelhardt, Shoumariyeh, Rösner, Ihorst, Biavasco, Meckel (CR17) 2020; 105
S Saadat (530_CR28) 2021; 325
530_CR22
530_CR21
L Moreno (530_CR44) 2019; 25
C Girmenia (530_CR24) 2019; 34
A Vijenthira (530_CR10) 2020; 136
J Krejcik (530_CR42) 2016; 128
FP Polack (530_CR25) 2020; 383
M Engelhardt (530_CR17) 2020; 105
WE Pierceall (530_CR43) 2020; 26
J Martínez-López (530_CR16) 2020; 10
M Hahn (530_CR39) 2015; 100
530_CR19
M Mikulska (530_CR38) 2019; 19
T Casneuf (530_CR41) 2021; 35
A Chari (530_CR8) 2020; 136
P Leone (530_CR36) 2020; 10
530_CR52
530_CR50
D Cucinotta (530_CR6) 2020; 91
LE Roeker (530_CR14) 2020; 34
530_CR4
T Liu (530_CR12) 2020; 147
F Costa (530_CR46) 2017; 8
M Gavriatopoulou (530_CR5) 2020; 21
ML Solodky (530_CR13) 2020; 31
KA Frerichs (530_CR45) 2020; 105
530_CR49
F Pimpinelli (530_CR31) 2021; 14
530_CR48
M Voysey (530_CR26) 2021; 397
K Yang (530_CR7) 2020; 21
SV Rajkumar (530_CR32) 2014; 15
N Le Bert (530_CR51) 2020; 584
M Gavriatopoulou (530_CR20) 2021; 5
CW Tan (530_CR34) 2020; 38
AC Walls (530_CR2) 2020; 181
G Chamilos (530_CR9) 2021; 72
K Nakamura (530_CR37) 2020; 136
530_CR33
530_CR30
H Ludwig (530_CR23) 2021; 35
M Hoffmann (530_CR1) 2020; 181
A Marra (530_CR11) 2021; 32
EE Walsh (530_CR35) 2020; 383
AR Branagan (530_CR40) 2017; 17
M Gavriatopoulou (530_CR3) 2020; 20
C Galustian (530_CR47) 2009; 58
C Dumontet (530_CR15) 2018; 32
530_CR29
E Terpos (530_CR18) 2020; 34
R Gharpure (530_CR27) 2021; 325
References_xml – ident: CR22
– volume: 31
  start-page: 1087
  year: 2020
  end-page: 8
  ident: CR13
  article-title: Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2020.04.475
  contributor:
    fullname: Herr
– volume: 383
  start-page: 2439
  year: 2020
  end-page: 50
  ident: CR35
  article-title: Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2027906
  contributor:
    fullname: Gurtman
– volume: 15
  start-page: e538
  year: 2014
  end-page: 548
  ident: CR32
  article-title: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70442-5
  contributor:
    fullname: Mateos
– volume: 128
  start-page: 384
  year: 2016
  end-page: 94
  ident: CR42
  article-title: Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
  publication-title: Blood
  doi: 10.1182/blood-2015-12-687749
  contributor:
    fullname: Plesner
– volume: 105
  start-page: e302
  year: 2020
  end-page: e306
  ident: CR45
  article-title: Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients
  publication-title: Haematologica
  doi: 10.3324/haematol.2019.231860
  contributor:
    fullname: Rimmelzwaan
– ident: CR49
– ident: CR4
– volume: 19
  start-page: e188
  year: 2019
  end-page: e199
  ident: CR38
  article-title: Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(18)30601-7
  contributor:
    fullname: Gallo
– volume: 136
  start-page: 2881
  year: 2020
  end-page: 92
  ident: CR10
  article-title: Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
  publication-title: Blood
  doi: 10.1182/blood.2020008824
  contributor:
    fullname: Fattizzo
– volume: 21
  start-page: 167
  year: 2020
  end-page: 79
  ident: CR5
  article-title: Emerging treatment strategies for COVID-19 infection
  publication-title: Clin Exp Med
  doi: 10.1007/s10238-020-00671-y
  contributor:
    fullname: Tzanninis
– ident: CR29
– volume: 32
  start-page: 113
  year: 2021
  end-page: 9
  ident: CR11
  article-title: Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2020.10.473
  contributor:
    fullname: Venturini
– volume: 35
  start-page: 573
  year: 2021
  end-page: 84
  ident: CR41
  article-title: Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
  publication-title: Leukemia
  doi: 10.1038/s41375-020-0855-4
  contributor:
    fullname: Vanhoof
– volume: 181
  start-page: 281
  year: 2020
  end-page: 92 e286
  ident: CR2
  article-title: Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.058
  contributor:
    fullname: Veesler
– volume: 17
  start-page: 296
  year: 2017
  end-page: 304.e292
  ident: CR40
  article-title: Clinical and serologic responses after a two-dose series of high-dose influenza vaccine in plasma cell disorders: a prospective, single-arm trial
  publication-title: Clin Lymphoma Myeloma Leuk
  doi: 10.1016/j.clml.2017.02.025
  contributor:
    fullname: Parker
– volume: 10
  year: 2020
  ident: CR16
  article-title: Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
  publication-title: Blood Cancer J
  doi: 10.1038/s41408-020-00372-5
  contributor:
    fullname: Lopez de la Guía
– volume: 91
  start-page: 157
  year: 2020
  end-page: 60
  ident: CR6
  article-title: WHO declares COVID-19 a pandemic
  publication-title: Acta Biomed
  contributor:
    fullname: Vanelli
– ident: CR21
– ident: CR19
– volume: 397
  start-page: 881
  year: 2021
  end-page: 91
  ident: CR26
  article-title: Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00432-3
  contributor:
    fullname: Aley
– volume: 136
  start-page: 3033
  year: 2020
  end-page: 40
  ident: CR8
  article-title: Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
  publication-title: Blood
  doi: 10.1182/blood.2020008150
  contributor:
    fullname: Yong
– volume: 10
  start-page: 599098
  year: 2020
  ident: CR36
  article-title: Actors on the scene: immune cells in the myeloma niche
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.599098
  contributor:
    fullname: Pappagallo
– volume: 20
  start-page: 493
  year: 2020
  end-page: 506
  ident: CR3
  article-title: Organ-specific manifestations of COVID-19 infection
  publication-title: Clin Exp Med
  doi: 10.1007/s10238-020-00648-x
  contributor:
    fullname: Kastritis
– volume: 8
  start-page: 53053
  year: 2017
  end-page: 67
  ident: CR46
  article-title: Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.18085
  contributor:
    fullname: Toscani
– volume: 34
  start-page: 84
  year: 2019
  end-page: 94
  ident: CR24
  article-title: Management of infectious complications in multiple myeloma patients: expert panel consensus-based recommendations
  publication-title: Blood Rev
  doi: 10.1016/j.blre.2019.01.001
  contributor:
    fullname: Di Raimondo
– ident: CR50
– volume: 383
  start-page: 2603
  year: 2020
  end-page: 15
  ident: CR25
  article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2034577
  contributor:
    fullname: Lockhart
– volume: 100
  start-page: e285
  year: 2015
  end-page: 288
  ident: CR39
  article-title: Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma
  publication-title: Haematologica
  doi: 10.3324/haematol.2014.116772
  contributor:
    fullname: Goldschmidt
– volume: 34
  start-page: 2000
  year: 2020
  end-page: 11
  ident: CR18
  article-title: Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
  publication-title: Leukemia
  doi: 10.1038/s41375-020-0876-z
  contributor:
    fullname: Ntanasis-Stathopoulos
– volume: 14
  start-page: 81
  year: 2021
  ident: CR31
  article-title: Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-021-01090-6
  contributor:
    fullname: Falcucci
– volume: 584
  start-page: 457
  year: 2020
  end-page: 62
  ident: CR51
  article-title: SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
  publication-title: Nature
  doi: 10.1038/s41586-020-2550-z
  contributor:
    fullname: Chia
– volume: 26
  start-page: 5895
  year: 2020
  end-page: 902
  ident: CR43
  article-title: Immunomodulation in pomalidomide, dexamethasone, and daratumumab-treated patients with relapsed/refractory multiple myeloma
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-1781
  contributor:
    fullname: Van Oekelen
– volume: 21
  start-page: 904
  year: 2020
  end-page: 13
  ident: CR7
  article-title: Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(20)30310-7
  contributor:
    fullname: Jiang
– volume: 38
  start-page: 1073
  year: 2020
  end-page: 8
  ident: CR34
  article-title: A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction
  publication-title: Nat Biotechnol
  doi: 10.1038/s41587-020-0631-z
  contributor:
    fullname: Tiu
– volume: 136
  start-page: 2731
  year: 2020
  end-page: 40
  ident: CR37
  article-title: Cancer immunoediting and immune dysregulation in multiple myeloma
  publication-title: Blood
  doi: 10.1182/blood.2020006540
  contributor:
    fullname: Martinet
– volume: 5
  start-page: e547
  year: 2021
  ident: CR20
  article-title: SARS-CoV-2 vaccines in patients with multiple myeloma
  publication-title: Hemasphere
  doi: 10.1097/HS9.0000000000000547
  contributor:
    fullname: Dimopoulos
– volume: 325
  start-page: 1670
  year: 2021
  end-page: 1
  ident: CR27
  article-title: First-dose COVID-19 vaccination coverage among skilled nursing facility residents and staff
  publication-title: JAMA
  doi: 10.1001/jama.2021.2352
  contributor:
    fullname: Link-Gelles
– ident: CR30
– volume: 147
  start-page: 3267
  year: 2020
  end-page: 9
  ident: CR12
  article-title: Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19
  publication-title: Int J Cancer
  doi: 10.1002/ijc.33148
  contributor:
    fullname: Wang
– ident: CR33
– volume: 181
  start-page: 271
  year: 2020
  end-page: 80.e278
  ident: CR1
  article-title: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.052
  contributor:
    fullname: Erichsen
– volume: 32
  start-page: 1404
  year: 2018
  end-page: 13
  ident: CR15
  article-title: A predictive model for risk of early grade >/= 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
  publication-title: Leukemia
  doi: 10.1038/s41375-018-0133-x
  contributor:
    fullname: Ludwig
– volume: 35
  start-page: 31
  year: 2021
  end-page: 44
  ident: CR23
  article-title: Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
  publication-title: Leukemia
  doi: 10.1038/s41375-020-01016-0
  contributor:
    fullname: Pawlyn
– ident: CR48
– volume: 325
  start-page: 1467
  year: 2021
  end-page: 9
  ident: CR28
  article-title: Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2
  publication-title: JAMA
  doi: 10.1001/jama.2021.3341
  contributor:
    fullname: Harris
– volume: 72
  start-page: 351
  year: 2021
  end-page: 6
  ident: CR9
  article-title: Are all patients with cancer at heightened risk for severe coronavirus disease 2019 (COVID-19)?
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciaa1079
  contributor:
    fullname: Kontoyiannis
– ident: CR52
– volume: 34
  start-page: 3047
  year: 2020
  end-page: 9
  ident: CR14
  article-title: Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia
  publication-title: Leukemia
  doi: 10.1038/s41375-020-01030-2
  contributor:
    fullname: Leslie
– volume: 25
  start-page: 3176
  year: 2019
  end-page: 87
  ident: CR44
  article-title: The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-1597
  contributor:
    fullname: Ajona
– volume: 58
  start-page: 1033
  year: 2009
  end-page: 45
  ident: CR47
  article-title: The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-008-0620-4
  contributor:
    fullname: Henry
– volume: 105
  start-page: 2872
  year: 2020
  end-page: 8
  ident: CR17
  article-title: Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany
  publication-title: Haematologica
  doi: 10.3324/haematol.2020.262758
  contributor:
    fullname: Meckel
– volume: 72
  start-page: 351
  year: 2021
  ident: 530_CR9
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciaa1079
  contributor:
    fullname: G Chamilos
– ident: 530_CR29
  doi: 10.1002/ajh.26185
– volume: 34
  start-page: 3047
  year: 2020
  ident: 530_CR14
  publication-title: Leukemia
  doi: 10.1038/s41375-020-01030-2
  contributor:
    fullname: LE Roeker
– volume: 35
  start-page: 573
  year: 2021
  ident: 530_CR41
  publication-title: Leukemia
  doi: 10.1038/s41375-020-0855-4
  contributor:
    fullname: T Casneuf
– volume: 34
  start-page: 2000
  year: 2020
  ident: 530_CR18
  publication-title: Leukemia
  doi: 10.1038/s41375-020-0876-z
  contributor:
    fullname: E Terpos
– volume: 26
  start-page: 5895
  year: 2020
  ident: 530_CR43
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-1781
  contributor:
    fullname: WE Pierceall
– ident: 530_CR22
  doi: 10.1001/jamaoncol.2021.1218
– volume: 325
  start-page: 1670
  year: 2021
  ident: 530_CR27
  publication-title: JAMA
  doi: 10.1001/jama.2021.2352
  contributor:
    fullname: R Gharpure
– volume: 397
  start-page: 881
  year: 2021
  ident: 530_CR26
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00432-3
  contributor:
    fullname: M Voysey
– volume: 325
  start-page: 1467
  year: 2021
  ident: 530_CR28
  publication-title: JAMA
  doi: 10.1001/jama.2021.3341
  contributor:
    fullname: S Saadat
– volume: 181
  start-page: 271
  year: 2020
  ident: 530_CR1
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.052
  contributor:
    fullname: M Hoffmann
– volume: 181
  start-page: 281
  year: 2020
  ident: 530_CR2
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.058
  contributor:
    fullname: AC Walls
– ident: 530_CR49
  doi: 10.1002/ajh.26248
– ident: 530_CR4
  doi: 10.1016/j.jinf.2021.05.004
– ident: 530_CR48
  doi: 10.1001/jama.2021.3341
– volume: 383
  start-page: 2439
  year: 2020
  ident: 530_CR35
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2027906
  contributor:
    fullname: EE Walsh
– volume: 25
  start-page: 3176
  year: 2019
  ident: 530_CR44
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-1597
  contributor:
    fullname: L Moreno
– volume: 20
  start-page: 493
  year: 2020
  ident: 530_CR3
  publication-title: Clin Exp Med
  doi: 10.1007/s10238-020-00648-x
  contributor:
    fullname: M Gavriatopoulou
– volume: 147
  start-page: 3267
  year: 2020
  ident: 530_CR12
  publication-title: Int J Cancer
  doi: 10.1002/ijc.33148
  contributor:
    fullname: T Liu
– volume: 35
  start-page: 31
  year: 2021
  ident: 530_CR23
  publication-title: Leukemia
  doi: 10.1038/s41375-020-01016-0
  contributor:
    fullname: H Ludwig
– volume: 10
  start-page: 599098
  year: 2020
  ident: 530_CR36
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.599098
  contributor:
    fullname: P Leone
– ident: 530_CR50
  doi: 10.1038/s41591-021-01377-8
– volume: 136
  start-page: 2881
  year: 2020
  ident: 530_CR10
  publication-title: Blood
  doi: 10.1182/blood.2020008824
  contributor:
    fullname: A Vijenthira
– volume: 105
  start-page: 2872
  year: 2020
  ident: 530_CR17
  publication-title: Haematologica
  doi: 10.3324/haematol.2020.262758
  contributor:
    fullname: M Engelhardt
– volume: 91
  start-page: 157
  year: 2020
  ident: 530_CR6
  publication-title: Acta Biomed
  contributor:
    fullname: D Cucinotta
– volume: 32
  start-page: 113
  year: 2021
  ident: 530_CR11
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2020.10.473
  contributor:
    fullname: A Marra
– volume: 5
  start-page: e547
  year: 2021
  ident: 530_CR20
  publication-title: Hemasphere
  doi: 10.1097/HS9.0000000000000547
  contributor:
    fullname: M Gavriatopoulou
– ident: 530_CR52
  doi: 10.3390/microorganisms9030546
– volume: 21
  start-page: 904
  year: 2020
  ident: 530_CR7
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(20)30310-7
  contributor:
    fullname: K Yang
– volume: 105
  start-page: e302
  year: 2020
  ident: 530_CR45
  publication-title: Haematologica
  doi: 10.3324/haematol.2019.231860
  contributor:
    fullname: KA Frerichs
– volume: 136
  start-page: 2731
  year: 2020
  ident: 530_CR37
  publication-title: Blood
  doi: 10.1182/blood.2020006540
  contributor:
    fullname: K Nakamura
– volume: 32
  start-page: 1404
  year: 2018
  ident: 530_CR15
  publication-title: Leukemia
  doi: 10.1038/s41375-018-0133-x
  contributor:
    fullname: C Dumontet
– ident: 530_CR30
  doi: 10.1182/blood.2021011904
– volume: 14
  start-page: 81
  year: 2021
  ident: 530_CR31
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-021-01090-6
  contributor:
    fullname: F Pimpinelli
– volume: 19
  start-page: e188
  year: 2019
  ident: 530_CR38
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(18)30601-7
  contributor:
    fullname: M Mikulska
– volume: 128
  start-page: 384
  year: 2016
  ident: 530_CR42
  publication-title: Blood
  doi: 10.1182/blood-2015-12-687749
  contributor:
    fullname: J Krejcik
– volume: 31
  start-page: 1087
  year: 2020
  ident: 530_CR13
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2020.04.475
  contributor:
    fullname: ML Solodky
– volume: 383
  start-page: 2603
  year: 2020
  ident: 530_CR25
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2034577
  contributor:
    fullname: FP Polack
– volume: 21
  start-page: 167
  year: 2020
  ident: 530_CR5
  publication-title: Clin Exp Med
  doi: 10.1007/s10238-020-00671-y
  contributor:
    fullname: M Gavriatopoulou
– ident: 530_CR21
  doi: 10.1002/ajh.26263
– ident: 530_CR19
  doi: 10.1111/bjh.17256
– volume: 38
  start-page: 1073
  year: 2020
  ident: 530_CR34
  publication-title: Nat Biotechnol
  doi: 10.1038/s41587-020-0631-z
  contributor:
    fullname: CW Tan
– volume: 584
  start-page: 457
  year: 2020
  ident: 530_CR51
  publication-title: Nature
  doi: 10.1038/s41586-020-2550-z
  contributor:
    fullname: N Le Bert
– volume: 17
  start-page: 296
  year: 2017
  ident: 530_CR40
  publication-title: Clin Lymphoma Myeloma Leuk
  doi: 10.1016/j.clml.2017.02.025
  contributor:
    fullname: AR Branagan
– volume: 10
  year: 2020
  ident: 530_CR16
  publication-title: Blood Cancer J
  doi: 10.1038/s41408-020-00372-5
  contributor:
    fullname: J Martínez-López
– volume: 8
  start-page: 53053
  year: 2017
  ident: 530_CR46
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.18085
  contributor:
    fullname: F Costa
– volume: 136
  start-page: 3033
  year: 2020
  ident: 530_CR8
  publication-title: Blood
  doi: 10.1182/blood.2020008150
  contributor:
    fullname: A Chari
– volume: 100
  start-page: e285
  year: 2015
  ident: 530_CR39
  publication-title: Haematologica
  doi: 10.3324/haematol.2014.116772
  contributor:
    fullname: M Hahn
– volume: 15
  start-page: e538
  year: 2014
  ident: 530_CR32
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70442-5
  contributor:
    fullname: SV Rajkumar
– ident: 530_CR33
– volume: 58
  start-page: 1033
  year: 2009
  ident: 530_CR47
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-008-0620-4
  contributor:
    fullname: C Galustian
– volume: 34
  start-page: 84
  year: 2019
  ident: 530_CR24
  publication-title: Blood Rev
  doi: 10.1016/j.blre.2019.01.001
  contributor:
    fullname: C Girmenia
SSID ssj0000561919
Score 2.5776882
Snippet Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against...
Abstract Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs)...
SourceID doaj
pubmedcentral
proquest
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Publisher
StartPage 138
SubjectTerms 13/1
14/1
631/250/2152/2153/1291
692/699/1541/1990/804
82/1
96/1
Antibodies
Biomedical and Life Sciences
Biomedicine
Cancer Research
Coronaviruses
COVID-19 vaccines
Hematology
Immunization
Multiple myeloma
Oncology
Severe acute respiratory syndrome coronavirus 2
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9UwELZQD4gLYhWBFhmJG1jN4i3H0lIVpMKFot4sr-JJbVI1eUiPP8FfZmwnr00lxIVrPImX-WzP2JNvEHpLjTdGMkuClZxQ6h3ROggSWmfi_uAbG887Tr_wkzP6-Zyd30r1FWPCMj1wHrh9qmUoqeGuKT3lnBkjfK25Y8HxltvsrZf0ljOVWb3BMaja6S-ZspH7AwVXQpIYkRCBB4vPYidKhP0LK_NujOSdi9K0_xw_Qg8nwxEf5AY_Rvd89wTdP52uxp-i36Bw3Pl1Orn4BZ_AMGYr07sNvs5xsB5f9cOID79-_3REqhb_1BZeTZrBqw5PDKsDjkez-HLjL_pLjVcDjozGFxs8p8sdMciD2Yjj6S3uQ6qHzPLbwPVn6Oz447fDEzJlWyCWVWIklkrbSBhWJyxjPgTQVKtp5aIVICoPhgyvbHA6MqhR1oSW-TZYwYx0PqZ-fI52ur7zLxD21EZHqCxtZanWwginwUywdS25ZJoW6N088uoqk2qodBneSJX1pKBSlfSkmgJ9iMrZSkZC7PQAYKImmKh_waRAu7Nq1TRLBwXuFCxwjRR1gd5si2F-xUsT3fl-nWViwvgaZMQCEosGLUu61Y_E1A3LpQAoFuj9DJ6byv_e4Zf_o8Ov0IM6gT1ifhftjNdrvwf202hep6nyB4D1Gmw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection (Proquest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIhLxVOEFmQkbmA1D79yQlCoClLhQtHeLD_pSm2ybLJIy5_gLzN2kq1SCa7xOE4yn-3PM5MZhF5R442RzJJgJSeUeke0DoKE2pm4P_jKRnvH2Rd-ek4_L9hiNLh1Y1jltCamhdq1NtrIj4D6AhgrKcq3q58kVo2K3tWxhMZtdKcoYbMFPIuF2NlYIjuui3r8VwY6H3UUDhSSxLiECD9Ygmb7UUrbP-OaNyMlb7hL0y50ch_tj_QRvxv0_QDd8s1DdPdsdJA_Qn9A7bjxm2S_-A23wPDllqZ1W7weomE9XrVdj4-_fv_0gRQ1_qUtdE36wcsGj3lWOxwNtPhq6y_bK42XHY55jS-3eCqa22OQB_KIow0XtyGNQyb5Xfj6Y3R-8vHb8SkZay4QywrRE0ulrSQLzgnLmA8B9FVrWrjIBUThgc7wwganYx41yqpQM18HK5iRzscCkE_QXtM2_inCntp4HMpzW1iqtTDCaSALtiwll0zTDL2evrxaDak1VHKJV1INelIwqEp6UlWG3kfl7CRjWux0oV3_UOMsU1TLkFPDXZV7yjkzRvhScwfvw2tu8wwdTqpV41zt1DWyMvRy1wyzLLpOdOPbzSATy8aXICNmkJg90LylWV6kfN2waAqAYobeTOC5HvzfL_zs_896gO6VCcYRzYdor19v_HPgR715kSbBX87pEWw
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKkRAXxFMsFGQkbmDIw68cEIJCVZAWLizqzfKzrLRNyiaLWP4Ef5mxkyxKVQ5c40kcz3xjz9jjGYSeUuONkcySYCUnlHpHtA6ChMqZuD740sb9jvknfrygH0_YyR4ayx0NDGwvde1iPanFevXi5_fta1D4V_2VcfmypeAlSBKDDSKmYF65gq4WtCxiiN98MPf7XN_gLqRaH0VGKQFdZ8M9mss_M1mrUkr_iR16MYrywlFqWqGObqIbg2mJ3_RYuIX2fH0bXZsPh-d30G-ABK79Ju1t_IJPYODq0jRui9d9pKzH503b4cPPXz-8I3mFf2gLrybZ4WWNhxysLY6bt_hs61fNmcbLFsecx6stHgvqdhjowbDEcX8XNyH1Q0b6XWj7XbQ4ev_l8JgM9RiIZbnoiKXSAsuCc8Iy5kMAWVaa5i7aCSL3YOrw3AanY441yspQMV8FK5iRzsfikPfQft3U_j7CntroKmWZzS3VWhjhNBgStigkl0zTGXo2cl6d92k3VDouL6Xq5aSgU5XkpMoZehuFs6OMKbPTg2Z9qgYNVFTLkFHDXZl5yjkzRvhCcwfj4RW32QwdjKJVIwwVOFwwBZZSFDP0ZNcMGhiPVXTtm01PE0vKF0AjJpCY_NC0pV5-S7m8YUIVAMsZej6C52_n_x7wg_9iz0N0vUiojuA-QPvdeuMfgSnVmcdJP_4ARm4aIg
  priority: 102
  providerName: Scholars Portal
– databaseName: SpringerOpen
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKKyEuFRQQaQtypd7AIg-_coSFqiC1XCjqzfJTrNQmVZOttP0T_GXGTrIoFRy4JuM49jf2jGfGMwgdU-ONkcySYCUnlHpHtA6ChNqZKB98ZaO94-ycn17Qr5fsckyTE-_CzPz3lXzfUTgBSBIDCSK_wJ7xCO2ADJbJMcsXG3tK1ITroh7vxfy96Uz2pBT9M73yYVTkA9dokjgnT9HuqCriDwO2z9CWb_bQ47PRGf4c_QKIceNXyVZxD5_AMEtL07o1vh0iXz2-abseL779-PKJFDW-0xaaJizwssFjTtUOR2Msvl77q_Za42WHYw7jqzWeCuT2GOhBUcTRXovbkPohE_0mVP0Fujj5_H1xSsb6CsSyQvTEUmkryYJzwjLmQwBsak0LF-W-KDyoLrywwemYM42yKtTM18EKZqTzsdjjS7TdtI1_hbCnNh598twWlmotjHAaFANblpJLpmmG3k4zr26GNBoqub8rqQacFHSqEk6qytDHCM6GMqbATg-AM9S4ohTVMuTUcFflnnLOjBG-1NzBeHjNbZ6hwwlaNa7LTsEBCra0SooyQ0eb17CioptEN75dDTSxRHwJNGLGErMfmr9plj9Tbm7YIAWwYobeTczzp_N_D3j__8gP0JMysXXk7kO03d-u_GvQjXrzJi2K38ZYCi4
  priority: 102
  providerName: Springer Nature
Title The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
URI https://link.springer.com/article/10.1038/s41408-021-00530-3
https://www.proquest.com/docview/2557303872
https://search.proquest.com/docview/2557546522
https://pubmed.ncbi.nlm.nih.gov/PMC8327056
https://doaj.org/article/4a8f04b6d30e4665bb7e2a6d5fd696c0
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF61Rar6gjiFoUSLxBu48bGXH2noAVJKhSjKm7UnRErsKHGQwp_gLzO7ttOmEi-8WLJ37F17vt05djyD0FuirFKC6thpwWJCrImldDx2hVFePthce3_H-Ipd3pDPEzrZQ7T_FyYE7Ws1Palm85Nq-jPEVi7metjHiQ2vxyNAIQfBPdxH-6Ab3jHR24TeYBOkRfeDTJKL4YqAFSFiH4zgMQfrzhE6zIlfv0OVt1t5FNL27-ia9yMl722XBil0_gg97NRH_KEd5mO0Z6sn6HDcbZA_RX-A7biy6-C_-A2PwPDlpqo2G7xso2EtXtSrBo--fP_0MU4L_EtquDXwB08r3OVZXWHvoMXzjZ3Vc4mnK-zzGs82uC-a22CgB-URex8url3oJ-7pt-Hrz9DN-dm30WXc1VyINU15E2sidC6oM4ZrSq1zwK9CktR4XYCnFtQZlmpnpM-jRmjuCmoLpzlVwlhfAPI5Oqjqyr5A2BLtzaEk0akmUnLFjQRlQWeZYIJKEqF3_ZcvF21qjTJsieeibFlWQqdlYFmZR-jUM2dL6dNihwv18kfZgaMkUriEKGbyxBLGqFLcZpIZeB9WMJ1E6LhnbdnN1VUJRhUsc7ngWYTebJthlvmtE1nZet3S-LLxGdDwHUjsDGi3BeAb8nV3cI3Q-x48t53_-4Vf_ndHr9BRFsDuMX-MDprl2r4G1alRA5gwEz5AD07Prq6_wtmIjeAsQG4Q3BFwvJikcBwTMQgT6y_FyyIc
link.rule.ids 230,315,729,782,786,866,887,2104,12063,21395,24325,27931,27932,31726,31727,33751,33752,38523,41127,42196,43317,43812,43902,51583,53798,53800,73752,74309,74419
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELegk4AXxKcoDDASb2CtSezYeUJsbOpgLQhtaG-WP6HSlpQmRSr_BP8yZ9fp1EnwGp_j2Hdn_3x3uUPoNdVOa8EM8UaUhFJniVKeE19ZHc4HV5hg75hMy_EZ_XjOzpPBrU1hlf2eGDdq25hgI98D6AvCWAiev5v_JKFqVPCuphIaN9FOSFWVD9DO_uH0y9eNlSXg4yqr0t8y0H2vpXClECREJgQBhE1o60SKifu30Ob1WMlrDtN4Dh3dQ3cTgMTv1xy_j264-gG6NUku8ofoDzAe124ZLRi_4RUY1m6mG7vCi3U8rMPzpu3wwedvxx9IVuFfykDXyCE8q3HKtNriYKLFlyt30VwqPGtxyGx8scJ92dwOAz3ARxysuLjxcRzS028C2B-hs6PD04MxSVUXiGEZ74ihwhSCeWu5Ycx5DxyrFM1sQAM8cwBoysx4q0ImNcoKXzFXecOZFtaFEpCP0aBuavcEYUdNuBCNRiYzVCmuuVUAF0yei1IwRYfoTb_ycr5OriGjU7wQcs0nCYPKyCdZDNF-YM6GMiTGjg-axXeZ9ExSJfyI6tIWI0fLkmnNXa5KC_Mpq9KMhmi3Z61M2trKK9kaolebZtCz4DxRtWuWa5pQOD4HGr4lElsftN1Sz37EjN2wbXIQxSF62wvP1eD_nvDT_3_rS3R7fDo5kSfH00_P0J08inSQ7F006BZL9xzQUqdfJJX4C3GsFcI
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSBUXVF5iaQEjcQNrN4kdOycELasWaOFA0d4sP8tKbbJsdpGWP8FfZuw4W6USXJNJnGS-sT_PTGYQekW101owQ7wRJaHUWaKU58RXVof1wRUm-DtOz8rjc_pxxmYp_6lNaZX9nBgnatuY4CMfA_UFMBaC52Of0iK-Hk3fLn6S0EEqRFpTO43b6A4vOAvdDPiMb_0tgSlXWZX-m4EbjVsKmwtBQo5CgCJMR4O1KZbwH_DOm1mTN0KncUWa7qF7iUrid53u76Nbrn6Adk9TsPwh-gMQwLVbR1_Gb7gFhq84143d4GWXGevwomlX-PDL95MjklX4lzJwadQVntc41VxtcXDW4quNu2yuFJ63ONQ4vtzgvoHuCoM8EEkc_Lm48XEc0stvU9kfofPph2-HxyT1XyCGZXxFDBWmEMxbyw1jznvQXaVoZgMv4JkDalNmxlsVaqpRVviKucobzrSwLjSDfIx26qZ2TxB21ISt0WRiMkOV4ppbBcTB5LkoBVN0hF73X14uujIbMobHCyE7PUkYVEY9yWKE3gflbCVDiex4oFleyGRxkirhJ1SXtpg4WpZMa-5yVVp4n7IqzWSEDnrVymS3rbxG2Qi93J4GiwthFFW7Zt3JhBbyOcjwASQGDzQ8U89_xNrdMIFygOIIvenBcz34v1_46f-f9QXaBVuQn0_OPu2ju3lEdAD2AdpZLdfuGdCmlX4e7eEvyQcYkw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+neutralizing+antibody+response+post+COVID-19+vaccination+in+patients+with+myeloma+is+highly+dependent+on+the+type+of+anti-myeloma+treatment&rft.jtitle=Blood+cancer+journal+%28New+York%29&rft.au=Terpos%2C+Evangelos&rft.au=Gavriatopoulou%2C+Maria&rft.au=Ntanasis-Stathopoulos%2C+Ioannis&rft.au=Briasoulis%2C+Alexandros&rft.date=2021-08-02&rft.issn=2044-5385&rft.eissn=2044-5385&rft.volume=11&rft.issue=8&rft_id=info:doi/10.1038%2Fs41408-021-00530-3&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41408_021_00530_3
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2044-5385&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2044-5385&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2044-5385&client=summon